Prescription figures show Novo Nordisk has a leading position in US  

2005.11.09
Newly published September prescription figures for insulin in USA show that Novo Nordisk has close to 40% share of the volume, slightly ahead of Eli Lilly

Newly published September prescription figures for insulin in USA show that Novo Nordisk has close to 40% share of the volume, which gives the Danish healthcare company a leading position for the first time on the US market, slightly ahead of competitor Eli Lilly.

Kåre Schultz, group chief executive of Novo Nordisk comments: "The next objective is clearly to become the largest company in terms of value. It is our experience that in the countries where we are well established, we typically have between 50-75% of the market. We think our products can achieve that in the US in the long term. It will however take several years to reach that target". Novo Nordisk currently has about 25-30% of the value of the US insulin market. The news was reported by financial daily newspaper Børsen.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. It also has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk is headquartered in Bagsværd, north of Copenhagen, and employs 21,200 people in 78 countries.

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×